Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > They sold shares on that earnings report?!?! Unbelievable

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Oct 14, 2021 3:23pm

175 Views

Post# 34006552

RE:RE:RE:They sold shares on that earnings report?!?! Unbelievable

That updated share amount came from page 5 of the Q3 financial statements. It looks like shares were issued for warrant conversions (221,900), a payment for Katanna (481,928), and shares issued due to options exercise (665,000) duringt he first nine months of 2021. I am not sure how much of that occurred in the third quarter though.